174 related articles for article (PubMed ID: 35595798)
1. Apparent regional differences in the spectrum of BARD1 pathogenic variants in Spanish population and importance of copy number variants.
Benito-Sánchez B; Barroso A; Fernández V; Mercadillo F; Núñez-Torres R; Pita G; Pombo L; Morales-Chamorro R; Cano-Cano JM; Urioste M; González-Neira A; Osorio A
Sci Rep; 2022 May; 12(1):8547. PubMed ID: 35595798
[TBL] [Abstract][Full Text] [Related]
2. Germline mutations of the BRCA1-associated ring domain (BARD1) gene in breast and breast/ovarian families negative for BRCA1 and BRCA2 alterations.
Ghimenti C; Sensi E; Presciuttini S; Brunetti IM; Conte P; Bevilacqua G; Caligo MA
Genes Chromosomes Cancer; 2002 Mar; 33(3):235-42. PubMed ID: 11807980
[TBL] [Abstract][Full Text] [Related]
3.
Rofes P; Del Valle J; Torres-Esquius S; Feliubadaló L; Stradella A; Moreno-Cabrera JM; López-Doriga A; Munté E; De Cid R; Campos O; Cuesta R; Teulé Á; Grau È; Sanz J; Capellá G; Díez O; Brunet J; Balmaña J; Lázaro C
Genes (Basel); 2021 Jan; 12(2):. PubMed ID: 33498765
[TBL] [Abstract][Full Text] [Related]
4. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.
Couch FJ; Shimelis H; Hu C; Hart SN; Polley EC; Na J; Hallberg E; Moore R; Thomas A; Lilyquist J; Feng B; McFarland R; Pesaran T; Huether R; LaDuca H; Chao EC; Goldgar DE; Dolinsky JS
JAMA Oncol; 2017 Sep; 3(9):1190-1196. PubMed ID: 28418444
[TBL] [Abstract][Full Text] [Related]
5. Literature Review of
Alenezi WM; Fierheller CT; Recio N; Tonin PN
Genes (Basel); 2020 Jul; 11(8):. PubMed ID: 32726901
[TBL] [Abstract][Full Text] [Related]
6. Nordic collaborative study of the BARD1 Cys557Ser allele in 3956 patients with cancer: enrichment in familial BRCA1/BRCA2 mutation-negative breast cancer but not in other malignancies.
Karppinen SM; Barkardottir RB; Backenhorn K; Sydenham T; Syrjäkoski K; Schleutker J; Ikonen T; Pylkäs K; Rapakko K; Erkko H; Johannesdottir G; Gerdes AM; Thomassen M; Agnarsson BA; Grip M; Kallioniemi A; Kere J; Aaltonen LA; Arason A; Møller P; Kruse TA; Borg A; Winqvist R
J Med Genet; 2006 Nov; 43(11):856-62. PubMed ID: 16825437
[TBL] [Abstract][Full Text] [Related]
7. Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer.
Weber-Lassalle N; Borde J; Weber-Lassalle K; Horváth J; Niederacher D; Arnold N; Kaulfuß S; Ernst C; Paul VG; Honisch E; Klaschik K; Volk AE; Kubisch C; Rapp S; Lichey N; Altmüller J; Lepkes L; Pohl-Rescigno E; Thiele H; Nürnberg P; Larsen M; Richters L; Rhiem K; Wappenschmidt B; Engel C; Meindl A; Schmutzler RK; Hahnen E; Hauke J
Breast Cancer Res; 2019 Apr; 21(1):55. PubMed ID: 31036035
[TBL] [Abstract][Full Text] [Related]
8. Cancer predisposing missense and protein truncating BARD1 mutations in non-BRCA1 or BRCA2 breast cancer families.
De Brakeleer S; De Grève J; Loris R; Janin N; Lissens W; Sermijn E; Teugels E
Hum Mutat; 2010 Mar; 31(3):E1175-85. PubMed ID: 20077502
[TBL] [Abstract][Full Text] [Related]
9. Variant Identification in BARD1, PRDM9, RCC1, and RECQL in Patients with Ovarian Cancer by Targeted Next-generation Sequencing of DNA Pools.
Suszynska M; Ratajska M; Galka-Marciniak P; Ryszkowska A; Wydra D; Debniak J; Jasiak A; Wasag B; Cybulski C; Kozlowski P
Cancer Prev Res (Phila); 2022 Mar; 15(3):151-160. PubMed ID: 34906988
[TBL] [Abstract][Full Text] [Related]
10. Functional analysis of clinical
Toh MR; Chong ST; Chan SH; Low CE; Ishak NDB; Lim JQ; Courtney E; Ngeow J
Cold Spring Harb Mol Case Stud; 2019 Aug; 5(4):. PubMed ID: 31371347
[TBL] [Abstract][Full Text] [Related]
11. Cancer predisposing BARD1 mutations in breast-ovarian cancer families.
Ratajska M; Antoszewska E; Piskorz A; Brozek I; Borg Å; Kusmierek H; Biernat W; Limon J
Breast Cancer Res Treat; 2012 Jan; 131(1):89-97. PubMed ID: 21344236
[TBL] [Abstract][Full Text] [Related]
12. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
13. Germline variants profiling of BRCA1 and BRCA2 in Chinese Hakka breast and ovarian cancer patients.
Zhang Y; Wu H; Yu Z; Li L; Zhang J; Liang X; Huang Q
BMC Cancer; 2022 Aug; 22(1):842. PubMed ID: 35918668
[TBL] [Abstract][Full Text] [Related]
14. Frequent incidence of BARD1-truncating mutations in germline DNA from triple-negative breast cancer patients.
De Brakeleer S; De Grève J; Desmedt C; Joris S; Sotiriou C; Piccart M; Pauwels I; Teugels E
Clin Genet; 2016 Mar; 89(3):336-40. PubMed ID: 26010302
[TBL] [Abstract][Full Text] [Related]
15. Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers.
Spurdle AB; Marquart L; McGuffog L; Healey S; Sinilnikova O; Wan F; Chen X; Beesley J; Singer CF; Dressler AC; Gschwantler-Kaulich D; Blum JL; Tung N; Weitzel J; Lynch H; Garber J; Easton DF; Peock S; Cook M; Oliver CT; Frost D; Conroy D; Evans DG; Lalloo F; Eeles R; Izatt L; Davidson R; Chu C; Eccles D; Selkirk CG; Daly M; Isaacs C; Stoppa-Lyonnet D; Sinilnikova OM; Buecher B; Belotti M; Mazoyer S; Barjhoux L; Verny-Pierre C; Lasset C; Dreyfus H; Pujol P; Collonge-Rame MA; ; Rookus MA; Verhoef S; Kriege M; Hoogerbrugge N; Ausems MG; van Os TA; Wijnen J; Devilee P; Meijers-Heijboer HE; Blok MJ; Heikkinen T; Nevanlinna H; Jakubowska A; Lubinski J; Huzarski T; Byrski T; Durocher F; Couch FJ; Lindor NM; Wang X; Thomassen M; Domchek S; Nathanson K; Caligo M; Jernström H; Liljegren A; Ehrencrona H; Karlsson P; ; Ganz PA; Olopade OI; Tomlinson G; Neuhausen S; Antoniou AC; Chenevix-Trench G; Rebbeck TR
Cancer Epidemiol Biomarkers Prev; 2011 May; 20(5):1032-8. PubMed ID: 21393566
[TBL] [Abstract][Full Text] [Related]
16. Is there more to BARD1 than BRCA1?
Irminger-Finger I; Jefford CE
Nat Rev Cancer; 2006 May; 6(5):382-91. PubMed ID: 16633366
[TBL] [Abstract][Full Text] [Related]
17. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
[TBL] [Abstract][Full Text] [Related]
18. [Association between single nucleotide polymorphism of BARD1 gene and BRCA1 gene mutation in epithelial ovarian cancer].
Liu WL; Zhao JZ; Wang ZZ; Dong B; Hou YY; Wu XX; Guo YJ
Zhonghua Fu Chan Ke Za Zhi; 2017 Jun; 52(6):403-410. PubMed ID: 28647964
[No Abstract] [Full Text] [Related]
19. Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients.
Rodríguez-Balada M; Roig B; Melé M; Albacar C; Serrano S; Salvat M; Querol M; Borràs J; Martorell L; Gumà J
Clin Biochem; 2020 Feb; 76():17-23. PubMed ID: 31786208
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer in East Africa: Prevalence and spectrum of germline SNV/indel and CNVs in BRCA1 and BRCA2 genes among breast cancer patients in Tanzania.
Rweyemamu LP; Gültaşlar BK; Akan G; Dharsee N; Namkinga LA; Lyantagaye SL; Yazıcı H; Atalar F
Cancer Med; 2023 Feb; 12(3):3395-3409. PubMed ID: 35908255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
